GELTEQ LIMITED ORDINARY SHARES
NASDAQ: GELS (Gelteq Limited)
Last update: 1 hour ago0.860
-0.03 (-3.54%)
| Previous Close | 0.892 |
| Open | 0.906 |
| Volume | 38,975 |
| Avg. Volume (3M) | 1,069,730 |
| Market Cap | 9,210,440 |
| Price / Sales | 84.72 |
| Price / Book | 1.03 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,518.17% |
| Diluted EPS (TTM) | -0.350 |
| Quarterly Revenue Growth (YOY) | 56.80% |
| Total Debt/Equity (MRQ) | 25.43% |
| Current Ratio (MRQ) | 0.080 |
| Operating Cash Flow (TTM) | -1.07 M |
| Return on Assets (TTM) | -8.04% |
| Return on Equity (TTM) | -21.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Gelteq Limited | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.00 |
|
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| % Held by Insiders | 60.36% |
| % Held by Institutions | 1.11% |
| Date | Type | Details |
|---|---|---|
| 16 Dec 2025 | Announcement | Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program |
| 09 Dec 2025 | Announcement | Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China |
| 05 Dec 2025 | Announcement | Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform |
| 02 Dec 2025 | Announcement | Gelteq to Present at Investor Summit Virtual on December 9, 2025 |
| 24 Nov 2025 | Announcement | Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform |
| 23 Oct 2025 | Announcement | Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform |
| 09 Oct 2025 | Announcement | Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |